[The effect of individual MHC subregions (RT1.A,B,D) and treatment with anti-RT1.D monoclonal antibody on survival of pancreatic islet allograft in the rat].
The present studies were undertaken to investigate the effect of the individual MHC subregions (RT1.A,B,D) and pretreatment with anti-RT1.D monoclonal antibody (MoAb) on survival of pancreatic islet allograft, using inbred, congenic, and recombinant rats which have different classes of histocompatibility barriers. Pancreatic islets were transplanted soon after isolation and after the treatment with anti-RT1.D MoAb. All syngenic islet allograft survived more than 90 days. The mean survival time (MST) of RT1.B,D incompatible combination (7.6 +/- 2.5 days) was significantly shorter than that of RT1.A incompatible combination (greater than 39.6 +/- 18.7 days). The MST of RT1.D incompatible combination (7.4 +/- 3.0 days) was significantly shorter than that of RT1.B incompatible combination (24.4 +/- 5.6 days). The MST of islet allograft, treated with donor specific and cytotoxic anti-RT1.D MoAb, in full-RT1 incompatible combination was prolonged up to 42.6 days (+/- 17.3 SD); this was statistically significant, when compared with that of untreated islet allograft in same combination (8.4 +/- 2.5 days). These results indicated that RT1.D region differences had a much more important role than RT1.A or RT1.B subregion differences in order to induce a strong rejection reaction in rat pancreatic islet allograft, and the treatment of islet with anti-RT1.D MoAb was very useful to prevent an acute rejection.